NCT03893825.
Study name | A study to test if TV‐46000 is safe for maintenance treatment of schizophrenia |
Methods | Randomised controlled trial. |
Participants | Schizophrenia, in maintenance/relapse prevention phase. |
Interventions | TV‐46000 (risperidone extended release injectable suspension) versus matching placebo. |
Outcomes | Number of adverse events, dropouts due to adverse events. |
Starting date | April 2019 |
Contact information | USMedInfo@tevapharm.com |
Notes |